efficacy

1:07
PACIFIC trial updates: durvalumab after chemotherapy in NSCLC
Marina Garassino
2:21
Current treatment landscape for ALK-positive NSCLC
Marina Garassino
2:10
Combining checkpoint inhibitors with chemotherapy for NSCLC
Marina Garassino
5:27
177Lu-PSMA-617 radionuclide therapy in mCRPC
Scott Tagawa
2:47
Rucaparib for urothelial carcinoma: the ATLAS study
Petros Grivas
2:06
Long-term benefits from hypoxia modification in bladder preservation: BCON trial update
Yee Pei Song
2:30
ABACUS updates: positive results for preoperative atezolizumab in bladder cancer
Thomas Powles
1:59
Real-world vs. clinical trial: efficacy of nivolumab in mRCC
Ugo De Giorgi
2:07
Impact of prior therapy on enzalutamide in nmCRPC: post-hoc analysis of PROSPER
Ugo De Giorgi
2:21
Looking to the future of RCC treatment
Michael Atkins
2:16
Savolitinib plus durvalumab show promise in papillary renal cancer: CALYPSO results
Thomas Powles
4:23
First-line therapy options for RCC: lessons from CheckMate 214 and KEYNOTE-427
Michael Atkins
2:52
DORA trial: radium-223 plus docetaxel for mCRPC
Michael Morris
3:10
KEYNOTE-426 rationale and results: pembro plus axitinib vs. sunitinib in mRCC
Thomas Powles
2:46
Early use of radium-223 is beneficial for asymptomatic mCRPC
Axel Heidenreich
1:45
Combined blockade of VEGF and PD-1 signaling in RCC
Michael Atkins
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals